8-K: Kiora Pharmaceuticals Inks $301 Million Deal with Tha Open Innovation for Retinal Disease Treatment

Kiora Pharmaceuticals has entered into a strategic agreement with Tha Open Innovation for the development and commercialization of KIO-301, a treatment for inherited retinal diseases, potentially worth up to $301 million.

Summary

• Kiora Pharmaceuticals has granted Tha Open Innovation (TOI) exclusive worldwide rights, excluding Asia, to develop and commercialize KIO-301 for degenerative retinal diseases.
• The agreement includes a $16 million upfront payment to Kiora.
• Kiora is eligible for up to $285 million in milestone payments based on clinical development, regulatory approvals, and commercial achievements.
• Kiora will also receive tiered royalties ranging from a high single digit to low twenty percent on net sales of KIO-301.
• Kiora will be primarily responsible for the design and implementation of clinical development through phase 2, with TOI reimbursing Kiora for these costs.
• TOI will be responsible for phase 3 clinical trials and securing regional marketing authorizations.
• Upon approval, TOI will handle all commercial activities, including sales and marketing.
• KIO-301 is a molecular photoswitch designed to restore vision in patients with inherited retinal diseases by conferring light-sensing capabilities to retinal ganglion cells.

Sentiment

Score: 9

Explanation: The document conveys a highly positive sentiment due to the significant partnership agreement, substantial upfront payment, potential for large milestone payments and royalties, and the validation of Kiora's technology. The deal significantly de-risks Kiora's development program and provides a clear path to commercialization.

Positives

• The partnership with TOI provides Kiora with strategic, financial, and commercial resources.
• Kiora's Phase 2 trial expenses for KIO-301 will be fully reimbursed by TOI.
• TOI will fund and conduct Phase 3 trials, reducing Kiora's financial burden.
• The deal extends Kiora's cash runway to at least late 2025.
• Kiora gains access to TOI's global commercial footprint and ophthalmic expertise.
• The agreement includes significant potential for long-term royalty upside for Kiora.
• KIO-301 has shown meaningful vision improvements in patients with late-stage retinitis pigmentosa in the ABACUS study.

Negatives

• Kiora is giving up exclusive commercialization rights for KIO-301 in the specified territories.
• Kiora is reliant on TOI for the success of Phase 3 trials and commercialization.
• The milestone payments are contingent on the achievement of specific clinical, regulatory, and commercial goals.
• The tiered royalties are subject to adjustment in certain circumstances.

Risks

• The success of KIO-301 is dependent on the outcome of clinical trials.
• Regulatory approvals may not be obtained on a timely basis or at all.
• Future trials of KIO-301 may not yield similar results to the ABACUS study.
• Market conditions and other factors could affect the commercial success of KIO-301.
• There is a risk that TOI may not successfully commercialize KIO-301.
• The agreement could be terminated under certain circumstances.

Future Outlook

Kiora anticipates initiating a Phase 2, multicenter, controlled clinical trial for retinitis pigmentosa in early 2024, with results expected in the first half of 2025. The company also plans to explore other retinal diseases where KIO-301 may be applicable. Kiora expects the partnership with TOI will help bring innovative treatments to market for patients living with inherited retinal disease.

Management Comments

• Brian Strem, Ph.D., CEO of Kiora, stated that the partnership with TOI provides the strategic, financial, and commercial resources needed to bring innovative treatments to market for patients with inherited retinal disease.
• Jean-Frdric Chibret, President of the Tha group, said that KIO-301 fits ideally into their range of therapeutic solutions as a cutting-edge product intended to return vision to patients suffering from hereditary retinal diseases.

Industry Context

This agreement highlights the growing interest in developing treatments for orphan retinal diseases. The partnership between a biotech company like Kiora and a global ophthalmic company like Tha reflects a trend of collaboration to bring innovative therapies to market. The focus on molecular photoswitches and gene-agnostic treatments is also a significant trend in the field.

Comparison to Industry Standards

• The deal structure, with an upfront payment, milestone payments, and tiered royalties, is typical for licensing agreements in the pharmaceutical industry.
• The total potential value of $301 million is significant, reflecting the potential market for treatments for inherited retinal diseases.
• The involvement of a major ophthalmic company like Tha provides validation for Kiora's technology and increases the likelihood of successful commercialization.
• Other companies developing treatments for retinal diseases include companies such as ProQR Therapeutics, AGTC, and REGENXBIO, which are also pursuing gene therapies and other novel approaches.
• The focus on a small molecule approach with KIO-301 is a differentiator compared to gene therapy approaches, which are more common in the space.

Stakeholder Impact

• Shareholders will benefit from the increased financial stability and potential for future revenue.
• Employees may see increased job security and opportunities for growth.
• Patients with inherited retinal diseases may have access to a new treatment option.
• Suppliers and partners may see increased business opportunities.
• Creditors may have increased confidence in Kiora's financial stability.

Next Steps

• Kiora will initiate a Phase 2 clinical trial for retinitis pigmentosa in early 2024.
• Kiora will continue to develop KIO-104 for posterior non-infectious uveitis.
• TOI will prepare for Phase 3 clinical trials and regional marketing authorizations for KIO-301.
• Kiora and TOI will collaborate on the development and commercialization of KIO-301.

Key Dates

Keywords

KIO-301, Retinitis Pigmentosa, Tha Open Innovation, Ophthalmology, License Agreement, Clinical Trials, Commercialization, Molecular Photoswitch, Orphan Retinal Diseases, Milestone Payments, Royalties